cimetidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H2-receptor antagonists, cimetidine derivatives	645	51481-61-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cimetidine tagamet tametin ulcedin ulcedine ulcerex ulcerfen cimetidine hydrochloride cimetidine HCl	A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Molecular weight: 252.34 Formula: C10H16N6S CLOGP: 0.38 LIPINSKI: 0 HAC: 6 HDO: 3 TPSA: 88.89 ALOGS: -3.16 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cimetidine
tagamet
tametin
ulcedin
ulcedine
ulcerex
ulcerfen
cimetidine hydrochloride
cimetidine HCl

A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.

Molecular weight: 252.34
Formula: C10H16N6S
CLOGP: 0.38
LIPINSKI: 0
HAC: 6
HDO: 3
TPSA: 88.89
ALOGS: -3.16
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O
0.80	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	6.20 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	62 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	158.51 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.78 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 16, 1977	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Body tinea	158.30	13.74	44	15061	1841	63472076
Urine abnormality	149.54	13.74	58	15047	6961	63466956
Inhibitory drug interaction	140.36	13.74	44	15061	2805	63471112
Infection susceptibility increased	131.20	13.74	44	15061	3477	63470440
Urine leukocyte esterase positive	118.75	13.74	41	15064	3538	63470379
Glucose tolerance impaired	107.78	13.74	45	15060	6532	63467385
Poor quality sleep	97.11	13.74	60	15045	19875	63454042
Lymphocyte count decreased	94.28	13.74	69	15036	30188	63443729
Purpura	89.90	13.74	47	15058	11338	63462579
Hyperlipidaemia	85.54	13.74	55	15050	19516	63454401
Bone density decreased	78.93	13.74	47	15058	14565	63459352
Impaired quality of life	78.83	13.74	46	15059	13737	63460180
Culture urine positive	73.36	13.74	29	15076	3658	63470259
Urine ketone body present	69.05	13.74	25	15080	2478	63471439
Impaired work ability	66.39	13.74	45	15060	17430	63456487
Drug intolerance	61.01	13.74	3	15102	308658	63165259
Blood urine present	60.11	13.74	40	15065	15029	63458888
Chronic kidney disease	57.23	13.74	62	15043	45336	63428581
Oral herpes	56.47	13.74	48	15057	26026	63447891
Skin disorder	51.35	13.74	48	15057	29459	63444458
Anaphylactoid reaction	49.57	13.74	22	15083	3701	63470216
Joint swelling	43.65	13.74	12	15093	327654	63146263
Erythema	41.32	13.74	113	14992	175638	63298279
Neutrophil count increased	41.16	13.74	33	15072	16494	63457423
Cataract	39.87	13.74	58	15047	56995	63416922
Cellulitis	36.52	13.74	68	15037	81890	63392027
Rheumatoid arthritis	36.31	13.74	8	15097	253811	63220106
Torsade de pointes	36.14	13.74	28	15077	13323	63460594
Keratitis	35.48	13.74	17	15088	3405	63470512
Hypertension	34.80	13.74	145	14960	279158	63194759
Band sensation	32.88	13.74	11	15094	862	63473055
Bacterial test positive	31.10	13.74	18	15087	5289	63468628
Specific gravity urine decreased	30.03	13.74	10	15095	772	63473145
Insomnia	29.38	13.74	115	14990	215137	63258780
Tri-iodothyronine free decreased	29.22	13.74	8	15097	316	63473601
Creatinine urine decreased	27.99	13.74	7	15098	193	63473724
Therapeutic product effect decreased	27.80	13.74	6	15099	193181	63280736
Product use issue	27.66	13.74	9	15096	220511	63253406
Arthropathy	27.05	13.74	11	15094	234781	63239136
Red cell distribution width increased	26.18	13.74	21	15084	10503	63463414
Circulatory collapse	25.97	13.74	29	15076	21909	63452008
Wound	25.79	13.74	4	15101	163259	63310658
Herpes zoster	25.63	13.74	59	15046	82403	63391514
Infusion site scar	25.42	13.74	8	15097	516	63473401
Contraindicated product administered	25.40	13.74	10	15095	217638	63256279
Urticaria	24.60	13.74	91	15014	165711	63308206
Infusion site discomfort	24.04	13.74	10	15095	1436	63472481
Systemic lupus erythematosus	23.72	13.74	10	15095	208908	63265009
Drug ineffective	23.65	13.74	149	14956	1044616	62429301
Electrocardiogram T wave amplitude decreased	23.56	13.74	7	15098	372	63473545
Product dose omission issue	22.46	13.74	14	15091	234299	63239618
Red blood cells urine positive	22.12	13.74	12	15093	3114	63470803
Blood thyroid stimulating hormone increased	21.48	13.74	16	15089	7178	63466739
Peripheral swelling	21.48	13.74	19	15086	265923	63207994
Protein urine present	21.45	13.74	15	15090	6105	63467812
Maternal exposure during pregnancy	21.30	13.74	13	15092	220049	63253868
Death	21.21	13.74	157	14948	374224	63099693
White blood cell count decreased	21.18	13.74	77	15028	139027	63334890
Anxiety	21.13	13.74	105	15000	217436	63256481
Red blood cell count decreased	21.01	13.74	36	15069	40609	63433308
Myelosuppression	20.94	13.74	27	15078	23676	63450241
Alanine aminotransferase increased	20.76	13.74	63	15042	103707	63370210
Basophil count increased	20.70	13.74	8	15097	949	63472968
Urobilinogen urine increased	20.62	13.74	6	15099	296	63473621
Intentional product use issue	20.50	13.74	3	15102	127889	63346028
Nitrite urine present	19.87	13.74	8	15097	1058	63472859
Flushing	19.36	13.74	50	15055	75037	63398880
Palmar-plantar erythrodysaesthesia syndrome	18.45	13.74	25	15080	22990	63450927
Hepatic enzyme increased	18.16	13.74	13	15092	202315	63271602
Food interaction	18.11	13.74	7	15098	831	63473086
Blood creatinine decreased	18.07	13.74	13	15092	5532	63468385
Infusion site rash	17.96	13.74	9	15096	1985	63471932
Chromaturia	17.93	13.74	21	15084	16696	63457221
Abdominal discomfort	17.47	13.74	31	15074	320854	63153063
Monocyte count decreased	17.31	13.74	9	15096	2144	63471773
Lower respiratory tract infection	17.30	13.74	5	15100	132302	63341615
Pancreatitis acute	16.67	13.74	26	15079	27140	63446777
White blood cells urine positive	16.59	13.74	12	15093	5146	63468771
Thyroid cyst	16.51	13.74	6	15099	601	63473316
Arthralgia	16.28	13.74	75	15030	569635	62904282
QRS axis abnormal	16.24	13.74	7	15098	1098	63472819
Bone marrow infiltration	15.81	13.74	6	15099	678	63473239
Platelet count decreased	15.78	13.74	62	15043	116060	63357857
Infusion site warmth	15.78	13.74	8	15097	1810	63472107
Glucose urine present	15.41	13.74	6	15099	726	63473191
Musculoskeletal stiffness	15.13	13.74	13	15092	184605	63289312
Visual acuity reduced	14.97	13.74	22	15083	21804	63452113
pH urine increased	14.88	13.74	5	15100	397	63473520
Red cell distribution width decreased	14.81	13.74	8	15097	2057	63471860
Anion gap decreased	14.68	13.74	5	15100	414	63473503
Immune thrombocytopenia	14.33	13.74	15	15090	10541	63463376
White blood cell count increased	14.27	13.74	34	15071	48527	63425390
Product use in unapproved indication	14.20	13.74	13	15092	179067	63294850
Drug exposure before pregnancy	14.00	13.74	6	15099	928	63472989
Haematocrit increased	13.92	13.74	8	15097	2318	63471599
Eosinophil count increased	13.89	13.74	15	15090	10913	63463004
Swelling	13.76	13.74	28	15077	275350	63198567

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	35.13	16.25	39	5888	41171	34909833
Renal injury	22.19	16.25	17	5910	11178	34939826
Mucosal erosion	20.38	16.25	7	5920	837	34950167
Palmar-plantar erythrodysaesthesia syndrome	18.06	16.25	18	5909	16777	34934227
Peptic ulcer	18.01	16.25	9	5918	2774	34948230
Decreased appetite	16.75	16.25	64	5863	166328	34784676

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urine abnormality	158.78	13.37	62	17566	8157	79718603
Body tinea	157.55	13.37	43	17585	1811	79724949
Inhibitory drug interaction	128.05	13.37	45	17583	4408	79722352
Infection susceptibility increased	128.01	13.37	43	17585	3678	79723082
Urine leukocyte esterase positive	116.33	13.37	41	17587	4050	79722710
Lymphocyte count decreased	99.57	13.37	83	17545	47206	79679554
Glucose tolerance impaired	98.80	13.37	44	17584	8040	79718720
Poor quality sleep	93.93	13.37	60	17568	22662	79704098
Bone density decreased	80.61	13.37	45	17583	13302	79713458
Hyperlipidaemia	77.13	13.37	56	17572	26037	79700723
Urine ketone body present	76.37	13.37	29	17599	3536	79723224
Impaired quality of life	74.83	13.37	44	17584	14342	79712418
Purpura	74.41	13.37	49	17579	19478	79707282
Culture urine positive	70.23	13.37	29	17599	4406	79722354
Impaired work ability	57.62	13.37	42	17586	19639	79707121
Oral herpes	55.32	13.37	47	17581	27407	79699353
Blood urine present	50.33	13.37	40	17588	21257	79705503
Hypertension	47.60	13.37	171	17457	330821	79395939
Skin disorder	46.78	13.37	47	17581	33896	79692864
Erythema	43.51	13.37	128	17500	223162	79503598
Anaphylactoid reaction	43.23	13.37	22	17606	5400	79721360
Cataract	39.35	13.37	58	17570	62062	79664698
Torsade de pointes	36.75	13.37	32	17596	19280	79707480
Off label use	36.41	13.37	93	17535	907122	78819638
Keratitis	35.81	13.37	18	17610	4304	79722456
Red cell distribution width increased	32.58	13.37	27	17601	15215	79711545
Insomnia	32.14	13.37	123	17505	245047	79481713
Joint swelling	31.83	13.37	12	17616	288634	79438126
Band sensation	30.68	13.37	10	17618	778	79725982
Flushing	30.41	13.37	63	17565	88205	79638555
Urticaria	30.35	13.37	100	17528	185101	79541659
Palmar-plantar erythrodysaesthesia syndrome	30.28	13.37	37	17591	33097	79693663
Specific gravity urine decreased	29.62	13.37	10	17618	868	79725892
Infusion site scar	28.90	13.37	8	17620	355	79726405
Infusion site discomfort	28.69	13.37	11	17617	1376	79725384
Alanine aminotransferase increased	28.64	13.37	90	17538	162480	79564280
Chronic kidney disease	28.63	13.37	52	17576	66102	79660658
Tri-iodothyronine free decreased	28.54	13.37	8	17620	372	79726388
Red blood cell count decreased	27.20	13.37	47	17581	57466	79669294
Bacterial test positive	26.70	13.37	18	17610	7431	79719329
Contusion	25.87	13.37	82	17546	148694	79578066
Monocyte count decreased	25.55	13.37	13	17615	3188	79723572
Haematocrit increased	25.45	13.37	14	17614	4020	79722740
White blood cell count decreased	24.28	13.37	94	17534	188194	79538566
Cellulitis	23.63	13.37	65	17563	108995	79617765
Therapeutic product effect decreased	23.44	13.37	4	17624	163859	79562901
Infusion site rash	23.18	13.37	10	17618	1692	79725068
Neutrophil count increased	22.40	13.37	30	17598	29366	79697394
Peptic ulcer	22.22	13.37	15	17613	6208	79720552
Creatinine urine decreased	21.86	13.37	6	17622	258	79726502
Therapeutic product effect incomplete	21.30	13.37	3	17625	141642	79585118
Basophil count increased	21.03	13.37	9	17619	1494	79725266
Rheumatoid arthritis	20.84	13.37	10	17618	208460	79518300
Herpes zoster	20.68	13.37	56	17572	93027	79633733
Secondary adrenocortical insufficiency	20.51	13.37	11	17617	3003	79723757
Protein urine present	19.73	13.37	17	17611	10095	79716665
Platelet count decreased	19.50	13.37	90	17538	194574	79532186
Ventricular tachycardia	19.47	13.37	34	17594	41901	79684859
Nitrite urine present	19.46	13.37	8	17620	1201	79725559
Mean cell haemoglobin increased	19.42	13.37	12	17616	4273	79722487
Drug ineffective	18.86	13.37	151	17477	1080762	78645998
Gastrooesophageal reflux disease	18.62	13.37	58	17570	104188	79622572
Arthropathy	18.48	13.37	8	17620	177103	79549657
Red cell distribution width decreased	18.40	13.37	9	17619	2029	79724731
Blood thyroid stimulating hormone increased	18.30	13.37	16	17612	9692	79717068
Infusion site warmth	18.03	13.37	8	17620	1447	79725313
White blood cells urine positive	17.86	13.37	13	17615	6062	79720698
Peripheral swelling	17.81	13.37	20	17608	269597	79457163
Product use in unapproved indication	17.17	13.37	18	17610	250341	79476419
Blood creatinine decreased	17.01	13.37	14	17614	7811	79718949
Drug exposure before pregnancy	16.70	13.37	6	17622	626	79726134
Contraindicated product administered	16.62	13.37	7	17621	157531	79569229
Wound	16.26	13.37	3	17625	116176	79610584
Urobilinogen urine increased	16.25	13.37	6	17622	677	79726083
Aspartate aminotransferase increased	16.09	13.37	67	17561	138574	79588186
Bone marrow infiltration	15.73	13.37	6	17622	740	79726020
Electrocardiogram T wave amplitude decreased	15.70	13.37	6	17622	744	79726016
Leukocyturia	15.67	13.37	8	17620	1975	79724785
Product dose omission issue	15.66	13.37	19	17609	247518	79479242
Product use issue	15.64	13.37	14	17614	209808	79516952
Circulatory collapse	15.53	13.37	29	17599	37639	79689121
Eosinophil count increased	15.46	13.37	19	17609	17086	79709674
Red blood cells urine positive	15.46	13.37	11	17617	4952	79721808
Myelosuppression	15.35	13.37	30	17598	40266	79686494
Hepatic function abnormal	15.26	13.37	43	17585	73064	79653696
Thyroid cyst	15.18	13.37	5	17623	402	79726358
Coronary artery disease	15.16	13.37	40	17588	65434	79661326
Anxiety	14.90	13.37	100	17528	248412	79478348
Infusion site pruritus	14.88	13.37	10	17618	4108	79722652
Blood alkaline phosphatase increased	14.84	13.37	39	17589	63625	79663135
pH urine increased	14.67	13.37	5	17623	447	79726313
Mean cell haemoglobin concentration increased	14.62	13.37	6	17622	897	79725863
Mucosal erosion	14.50	13.37	8	17620	2310	79724450
Gamma-glutamyltransferase increased	14.31	13.37	35	17593	54645	79672115
Anaphylactic shock	13.96	13.37	27	17601	35969	79690791
Pericarditis	13.94	13.37	3	17625	104233	79622527
Duodenal ulcer haemorrhage	13.89	13.37	12	17616	7151	79719609
Food interaction	13.84	13.37	7	17621	1695	79725065
Dyspepsia	13.78	13.37	54	17574	108633	79618127
Blood lactate dehydrogenase increased	13.53	13.37	28	17600	39142	79687618

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02BA01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists
ATC	A02BA51	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists
FDA MoA	N0000000151	Histamine H2 Receptor Antagonists
CHEBI has role	CHEBI:37961	H2 receptor antagonists
CHEBI has role	CHEBI:49201	anti-ulcer drugs
CHEBI has role	CHEBI:50183	P450 inhibitors
CHEBI has role	CHEBI:60809	adjuvants
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D065609	Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006635	Histamine H2 Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D018377	Neurotransmitter Agents
FDA EPC	N0000175784	Histamine-2 Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Heartburn	indication	16331000
Upper gastrointestinal hemorrhage	indication	37372002
Duodenal ulcer disease	indication	51868009	DOID:1724
Zollinger-Ellison syndrome	indication	53132006	DOID:0050782
Multiple endocrine adenomas	indication	60549007
Indigestion	indication	162031009
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Systemic mast cell disease	indication	397016004	DOID:349
Gastric ulcer	indication	397825006	DOID:10808
Upper GI Bleed Prevention	indication
Maintenance of Healing Duodenal Ulcer	indication
Pancreatic insufficiency	off-label use	37992001
Urticaria	off-label use	126485001
Prevention of Stress Ulcer	off-label use
NSAID-Induced Gastric Ulcer	off-label use
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Malignant tumor of stomach	contraindication	363349007	DOID:10534

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.83	acidic
pKa2	6.71	Basic
pKa3	0.0	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN	ANTAGONIST	Kd	6.14	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.16	PDSP
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	5.92	CHEMBL
Multidrug and toxin extrusion protein 2	Transporter	Q86VL8	S47A2_HUMAN	INHIBITOR	Ki	5.10	IUPHAR
Histamine H2 receptor	GPCR		HRH2_CAVPO		Kd	6.58	CHEMBL
Histamine H2 receptor	GPCR		HRH2_RAT	ANTAGONIST	Ki	5.90	IUPHAR

External reference:

ID	Source
4018845	VUID
N0000147147	NUI
D00295	KEGG_DRUG
70059-30-2	SECONDARY_CAS_RN
152402	RXNORM
4018844	VANDF
4018845	VANDF
C0008783	UMLSCUI
CHEBI:3699	CHEBI
CHEMBL30	ChEMBL_ID
CHEMBL1201051	ChEMBL_ID
DB00501	DRUGBANK_ID
D002927	MESH_DESCRIPTOR_UI
2756	PUBCHEM_CID
1231	IUPHAR_LIGAND_ID
3765	INN_ID
80061L1WGD	UNII
101	MMSL
2261	MMSL
4448	MMSL
4449	MMSL
6098	MMSL
d00140	MMSL
003415	NDDF
004987	NDDF
373541007	SNOMEDCT_US
83051006	SNOMEDCT_US
83532008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8192	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8192	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8192	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8204	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8204	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8204	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8305	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8305	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8305	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
Good Sense Heartburn Relief	HUMAN OTC DRUG LABEL	1	0113-0022	TABLET, FILM COATED	200 mg	ORAL	ANDA	16 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0649	SOLUTION	300 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0649	SOLUTION	300 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1298	SOLUTION	400 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1298	SOLUTION	400 mg	ORAL	ANDA	15 sections
cimetidineacid reducer	HUMAN OTC DRUG LABEL	1	0363-0022	TABLET, FILM COATED	200 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0053	TABLET, FILM COATED	200 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0317	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0372	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0541	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1282	TABLET	400 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	10544-626	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	10544-627	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-048	TABLET, FILM COATED	300 mg	ORAL	ANDA	17 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-265	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-372	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-531	TABLET	300 mg	ORAL	ANDA	14 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-532	TABLET	400 mg	ORAL	ANDA	14 sections
Good Neighbor Pharmacy Heartburn Relief	HUMAN OTC DRUG LABEL	1	24385-111	TABLET, FILM COATED	200 mg	ORAL	ANDA	16 sections
Acid Reducer	HUMAN OTC DRUG LABEL	1	30142-323	TABLET, FILM COATED	200 mg	ORAL	ANDA	16 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	33261-024	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections